Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2015-01-29 | Quotient (Jersey) Ortho Clinical Diagnostics, a J&J company (USA - NJ) | MosaiQ™ platform | transfusion diagnostic | commercialisation distribution |
Technology - Services - Diagnostic - Transfusion | Commercialisation agreement |
2015-01-29 | Nabriva Therapeutics (Austria) | nomination |
Infectious diseases | Nomination | ||
2015-01-28 | Dimension Therapeutics (USA - MA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
2015-01-28 | Galmed Pharmaceuticals (Israel) Perrigo (Ireland) | aramchol | NASH (non-alcoholic steatohepatitis) | manufactuiring - production | Hepatic diseases - Liver diseases | Production agreement |
2015-01-27 | Immutep (France) now Prima BioMed (Australia) GSK (UK) | ImmuTune® IMP731 and any other depleting LAG-3 antibodies | Autoimmune diseases | licensing |
Autoimmune diseases | Milestone |
2015-01-27 | Bayer Healthcare (Germany) Janssen R&D, a J&J company (USA - NJ) Population Health Research Institute (PHRI) (Canada) Canadian Stroke Prevention Intervention Network (C-SPIN) (Canada) | rivaroxaban | embolic stroke of undetermined source | clinical research |
Cardiovascular diseases | Clinical research agreement |
2015-01-27 | Macrogenics (USA - MD) Janssen Biotech, a J&J company (USA - NJ) | duvortuxizumab -MGD011 | B-cell hematological malignancies | licensing | Cancer - Oncology | Termination of an agreement |
2015-01-26 | Saniona (Denmark) Pfizer (USA - NY) | small molecules targeting ion channels | R&D development |
Neurological diseases | Milestone | |
2015-01-26 | Gilead Sciences (USA - CA) Mylan Laboratories (indian subsidiary of Mylan, USA - PA) | sofosbuvir, GS-5816 | hepatitis C | licensing |
Infectious diseases | Licensing agreement |
2015-01-23 | Novartis (Switzerland) Incyte Pharmaceuticals (USA - DE) | INCB18424 [Jakafi®/Jakavi®], INCB28060 | myelofibrosis, multiple cancers | development licensing commercialisation |
Cancer - Oncology - Rare diseases - Hematological diseases | Milestone |
2015-01-23 | Agenus (USA - MA) Incyte (USA - DE) | immuno-therapeutics including checkpoint modulator antibodies directed against GITR, OX40, LAG-3 and TIM-3 | licensing development commercialisation |
Cancer - Oncology | Licensing agreement | |
2015-01-23 | Promethera Biosciences (Belgium) | resignation |
Hepatic diseases - Liver diseases - Rare diseases - Regenerative medicine | Resignation | ||
2015-01-23 | Array BioPharma (USA - CO) Novartis (Switzerland) | encorafenib (LGX818) | advanced tumors including melanoma and metastatic colorectal cancer | licensing |
Cancer - Oncology | Licensing agreement |
2015-01-22 | AstraZeneca (UK) Heptares Therapeutics (UK) | new medicines targeting G-protein coupled receptors (GPCRs) | CNS diseases - Cardiovascular diseases - Metabolic diseases - Inflammatory diseases | R&D |
CNS diseases - Cardiovascular diseases - Metabolic diseases - Inflammatory diseases | Milestone |
2015-01-22 | Kite Pharma (USA - CA) Tel Aviv Sourasky Medical Center (Israel) | CAR T cell therapy | collaboration |
Cancer - Oncology | Collaboration agreement | |
2015-01-22 | Ariad Pharmaceuticals (USA - MA) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
2015-01-22 | bioMerieux (France) Astute Medical (USA - CA) | NephroCheck® Test | acute kidney injury | development |
Kidney diseases - Renal diseases - Diagnostic | Development agreement |
2015-01-22 | ImmuPharma (UK) Simbec-Orion (UK) | Lupuzor™ (rigerimod) | systemic lupus erythematosus | clinical research |
Autoimmune diseases | Clinical research agreement |
2015-01-22 | BioInvent (Sweden) | nomination |
Nomination | |||
2015-01-21 | Glycovaxyn (Switzerland) Janssen Pharmaceuticals - J&J (USA) | multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology | infections caused by Extra-intestinal Pathogenic Escherichia coli (ExPEC), such as urinary tract infections (UTIs) | R&D |
Infectious diseases | Milestone |